Surrozen, Inc.
SRZNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Surrozen, Inc. (SRZN) is listed under Biotechnology. Valued at $267.5M, SRZN is a micro-cap name in its sector. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Market Cap
$267.5M
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
-5.44
EPS (TTM)
$-40.06
EPS (Fwd)
$-4.19
ROE
—
ROA
-25.4%
Cash
$102.0M
Total Debt
$6.3M
Free CF
-$21.8M
52W Change
94.5%
Annual Financials
Cash vs Debt
Where SRZN stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, SRZN finished 13.04% below its 150-day moving average ($25.53) and 7.23% below its 200-day moving average ($23.93). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SRZN overbought or oversold?
At the September 2, 2026 close, SRZN's RSI(14) was 32.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $102.0M in cash and $6.3M in debt, SRZN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$21.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
The relatively low beta of 0.56 suggests SRZN is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Surrozen, Inc. and its sector.